A Review on Potent Antitubercular Agent Isoniazid and Its Analogues

Abstract

ABSTRACT:There has been considerable interest in the development of new anti tubercular agents particularly against multidrug resistance and extensively drug resistant strain of tuberculosis because mycobacterium species have developed resistant against currently used drugs. The currently use antitubercular drugs having toxic effect and long period of therapeutic treatment. Therefore, many researchers have synthesized various newer drugs and analogues of currently used drugs for tuberculosis treatment. These observations have been guiding for the development of newer analogues that possess potent antitubercular activity with minimum side effects with effectiveness against multidrug resistant mycobacterium, and also in patient co-infected with HIV/AIDS. In this review we are discussed about isoniazid and it analogues as potent antitubercular agents.

Cytotoxicity of new pyridazin‐3(2H)‐one derivatives orchestrating oxidative stress in human triple‐negative breast cancer (MDA‐MB‐468)

“…Pyridazin‐3(2 H )‐one derivatives constitute an interesting class of heterocyclic lead compounds for drug discovery and research into anticancer molecules . Recently, it was reported that some pyridazin‐3(2 H )‐one derivatives specifically interact with and inhibit PIM (potential tumor targets) kinases with low nanomolar potency . In addition, pyridazin‐3(2 H )‐ones are endowed with many biological activities .…”

A magnetically-separable H 3 PW 12 O 40 @Fe 3 O 4 /EN-MIL-101 catalyst for the one-pot solventless synthesis of 2H-indazolo[2,1- b ] phthalazine-triones

“…Recently, phthalazine heterocyclic derivatives have attracted attention due to their high therapeutic value in analgesic, anti-inflammatory, antimicrobial, antithrombotic, antidepressant, diuretics, antihypertensive, antitubercular, and anti-HIV treatments [22]. Flexible synthetic routes to new scaffolds for generating various drug-based phthalazines thus represent a high of priority for catalyst design [22][23][24].…”

“…Recently, phthalazine heterocyclic derivatives have attracted attention due to their high therapeutic value in analgesic, anti-inflammatory, antimicrobial, antithrombotic, antidepressant, diuretics, antihypertensive, antitubercular, and anti-HIV treatments [22]. Flexible synthetic routes to new scaffolds for generating various drug-based phthalazines thus represent a high of priority for catalyst design [22][23][24]. In this context, previous research has focused on catalytic functions immobilized on nanoparticles [25][26][27][28][29][30], wherein the catalytic surface area is related to the particle size and shape, and is generally too low to provide high activity.…”

Antitubercular drugs: advances in nitrogen containing heterocyclic compounds and some other derivatives

“…This is considered a major contributing factor to long drug treatments for TB. 12 For this reason, it is important to determine if compounds have potential activity against these bacteria at the onset of design. The physicochemical properties were also studied that directly affect the pharmacokinetics and pharmacodynamics of drugs.…”

“…Compounds missing N--oxide groups have led to the loss of anti--TB activity. Over 500 derivatives of quinoxaline (12) were studied and it clearly demonstrated the importance of this group for developing a new class of anti--TB compounds. The quinoxaline compounds have activity on non--replicating bacteria, which could lead to shorter anti--TB activity.…”